Skip to content
Evigrade
CriticalDirect thrombin inhibitor×Antiepileptic, hydantoin derivative (sodium channel blocker)

Updated · Methodology

Mechanism

Dabigatran is a substrate of the efflux transporter P-glycoprotein (P-gp) and cytochrome P450 enzymes do not metabolise it (dabigatran label, US Food and Drug Administration, FDA). The EU dabigatran SmPC lists phenytoin among the P-gp inducers and expects co-administration to lower dabigatran plasma levels (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). The SmPC does not say how far levels fall with phenytoin. With another inducer, rifampicin, dabigatran peak concentration fell by 65.5% and total exposure by 67% (dabigatran SmPC, EMA). Dabigatran also appears in the phenytoin documents. The Spanish SmPC lists it among the drugs whose levels or effects phenytoin may alter (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and the US label among the drugs whose levels phenytoin decreases (phenytoin label, FDA).

Symptoms

The main risk is thrombosis because dabigatran works less well. In atrial fibrillation, this means stroke or systemic embolism, and in venous thromboembolism a recurrence of deep vein thrombosis or pulmonary embolism. Signs include leg swelling and pain, sudden shortness of breath and chest pain, sudden weakness or numbness of an arm, a leg or one side of the face, and difficulty speaking. The European Heart Rhythm Association guide also reports the opposite signal for direct oral anticoagulants as a group. In one case series, the risk of bleeding with phenytoin was higher. In a retrospective cohort from Taiwan, bleeding was more frequent when phenytoin was prescribed at the same time. The authors note that this result may not apply to other patient groups (EHRA 2021).

Management

The combination is contraindicated in the practical guide of the European Heart Rhythm Association (EHRA): its antiepileptic drug table marks the dabigatran and phenytoin cell as contraindicated because of reduced anticoagulant levels (EHRA 2021). The EU dabigatran SmPC says to avoid combining dabigatran with P-glycoprotein (P-gp) inducers and names phenytoin among them (dabigatran summary of product characteristics, SmPC, European Medicines Agency, EMA). The US label says that use with P-gp inducers, such as rifampicin, should generally be avoided (dabigatran label, US Food and Drug Administration, FDA). The dosing sections of the dabigatran labels give no specific dose for use with P-gp inducers (dabigatran SmPC, EMA, and label, FDA). When phenytoin is started or stopped, the dose of dabigatran and other drugs on the US label's list may need adjustment (phenytoin label, FDA). Phenytoin may also alter the levels or effects of other oral anticoagulants: warfarin, apixaban, edoxaban and rivaroxaban (phenytoin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dabigatran

Other interactions with Phenytoin